CD274 and neoplasm: Furthermore, our multiplexed proteomic analyses targeting PD-L1 and IFNy as key soluble immune proteins in plasma, as compared to PD-L1 and IFNy gene expression signatures in tumor tissue, contributed to the longitudinal monitoring in the index patient and to better identify a potential pseudo progression to the immune checkpoint inhibitor atezolizumab, before complete clinical response to cisplatin-based chemotherapy was observed.